Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

Yonsei University

Status: Completed

Conditions: Non-thyroidal Illness Syndrome

Treatments: Drug: liothyronine sodium; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01153360

4-2010-0086

Details and patient eligibility

About

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Enrollment: 100 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are undergoing Off-pump coronary artery bypass graft

Exclusion criteria

• No normal sinus rhythm,
• History of thyroid disease
• Abnormal thyroid hormone
• Renal dysfunction
• Hepatic dysfunction
• LVEF <30%
• Recent MI
• Active infection 1~15

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups

T3

Experimental group

Description:

triiodothyronine

Treatment:

Drug: liothyronine sodium

cyanocobalamin

Active Comparator group

Description:

vitamin B12

Treatment:

Drug: placebo